Seyyed Amir Hosseini, Saman Hashemi, Davood Siamian, Ali Asghari, Mohammad Fathollahzadeh, Hamidreza Majidiani, Iman Shahraki, Mohamad Hosein Safari
{"title":"Discovery of novel vaccine candidates based on the immunogenic epitopes derived from <i>Toxoplasma</i> membrane proteins.","authors":"Seyyed Amir Hosseini, Saman Hashemi, Davood Siamian, Ali Asghari, Mohammad Fathollahzadeh, Hamidreza Majidiani, Iman Shahraki, Mohamad Hosein Safari","doi":"10.7774/cevr.2025.14.e4","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Due to the widespread distribution and importance of <i>Toxoplasma gondii</i> infection as a parasitic zoonosis, multi-epitope vaccine design was implemented using a set of immunodominant epitopes screened out of a wide scope of membrane proteins.</p><p><strong>Materials and methods: </strong>On this basis, 5 vaccine candidates were created using linkers ([GGGGS]<sub>2</sub>, KK, AAY, GPGPG, GDGDG, EAAAK) and adjuvants (RS-09 peptide, <i>Mycobacterium tuberculosis</i> resuscitation-promoting factor E [RpfE] and 50S ribosomal protein, human interferon [IFN]-γ).</p><p><strong>Results: </strong>Polytopes with RS-09 alone (Toxo-App) and with IFN-γ (Toxo-Apfn), and one with 50S ribosomal protein (Toxo-Ribos) showed the highest immunogenicity during <i>in silico</i> prediction, and their 3-dimensional structure was refined. Protein-protein docking and molecular dynamics simulation analysis was done between the Toxo-App and human toll-like receptor (TLR)-4, rendering a stable connection. Codon optimization and <i>in silico</i> cloning was done ultimately for the selected vaccine candidate.</p><p><strong>Conclusion: </strong>In conclusion, potent multi-epitope vaccine candidates were designed against toxoplasmosis using a diverse set of <i>in silico</i> techniques, while further wet experiments are recommended.</p>","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"14 1","pages":"86-100"},"PeriodicalIF":2.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11799584/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Vaccine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7774/cevr.2025.14.e4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/13 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Due to the widespread distribution and importance of Toxoplasma gondii infection as a parasitic zoonosis, multi-epitope vaccine design was implemented using a set of immunodominant epitopes screened out of a wide scope of membrane proteins.
Materials and methods: On this basis, 5 vaccine candidates were created using linkers ([GGGGS]2, KK, AAY, GPGPG, GDGDG, EAAAK) and adjuvants (RS-09 peptide, Mycobacterium tuberculosis resuscitation-promoting factor E [RpfE] and 50S ribosomal protein, human interferon [IFN]-γ).
Results: Polytopes with RS-09 alone (Toxo-App) and with IFN-γ (Toxo-Apfn), and one with 50S ribosomal protein (Toxo-Ribos) showed the highest immunogenicity during in silico prediction, and their 3-dimensional structure was refined. Protein-protein docking and molecular dynamics simulation analysis was done between the Toxo-App and human toll-like receptor (TLR)-4, rendering a stable connection. Codon optimization and in silico cloning was done ultimately for the selected vaccine candidate.
Conclusion: In conclusion, potent multi-epitope vaccine candidates were designed against toxoplasmosis using a diverse set of in silico techniques, while further wet experiments are recommended.
期刊介绍:
Clin Exp Vaccine Res, the official English journal of the Korean Vaccine Society, is an international, peer reviewed, and open-access journal. It covers all areas related to vaccines and vaccination. Clin Exp Vaccine Res publishes editorials, review articles, special articles, original articles, case reports, brief communications, and correspondences covering a wide range of clinical and experimental subjects including vaccines and vaccination for human and animals against infectious diseases caused by viruses, bacteria, parasites and tumor. The scope of the journal is to disseminate information that may contribute to elaborate vaccine development and vaccination strategies targeting infectious diseases and tumors in human and animals. Relevant topics range from experimental approaches to (pre)clinical trials for the vaccine research based on, but not limited to, basic laboratory, translational, and (pre)clinical investigations, epidemiology of infectious diseases and progression of all aspects in the health related issues. It is published printed and open accessed online issues (https://ecevr.org) two times per year in 31 January and 31 July. Clin Exp Vaccine Res is linked to many international databases and is made freely available to institutions and individuals worldwide